EWTX

Edgewise Therapeutics Inc

Add to Watchlist

Advanced Chart

12.680

-0.27(-2.085%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.1801

Open

12.990

VWAP

12.78

Vol

568.06K

Mkt Cap

1.34B

Low

12.460

Amount

7.26M

EV/EBITDA(TTM)

Total Shares

93.41M

768.35M

EV/OCF(TTM)

P/S(TTM)

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

11 Analyst Rating

206.15% Upside

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 38.82 USD with a low forecast of 14.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

2 Hold

0 Sell

Strong Buy

206.15% Upside

Current: 12.680

Low

14.00

Averages

38.82

High

51.00

206.15% Upside

Current: 12.680

Low

14.00

Averages

38.82

High

51.00

Raymond James

Martin Auster

Strong Buy

initiated

$46

2025-07-29

Reason

Raymond James

Martin Auster

Price Target

$46

2025-07-29

initiated

Strong Buy

Reason

Raymond James analyst Martin Auster initiated coverage of Edgewise Therapeutics with a Strong Buy rating and $46 price target. The firm sees a highly attractive risk/reward profile for the shares at current levels. Edgewise's Phase 2 CIRRUS-HCM Part D results in the second half of 2025 can "meaningfully de-risk" EDG-7500 in hypertrophic cardiomyopathy, the analyst tells investors in a research note. The firm sees a path forward for the drug to potentially avoid a risk evaluation and mitigation strategy.

H.C. Wainwright

Buy

initiated

$42

2025-06-30

Reason

H.C. Wainwright

Price Target

$42

2025-06-30

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Edgewise Therapeutics with a Buy rating and $42 price target. The clinical-stage biotechnology company focused on developing orally delivered small molecule inhibitors for severe muscle diseases is currently advancing two candidates on its clinical pipeline: sevasemten, which is designed to protect contraction-induced muscle damage caused by dystrophinopathies, including Becker muscular dystrophy and Duchenne muscular dystrophy, and EDG-7500 for both obstructive and non-obstructive forms of hypertrophic cardiomyopathy. The firm sees potential for sevasemten to become the first approved drug for BMD, and an adjuvant for DMD, and for EDG-7500 as "a valid alternative" to cardiac myosin inhibitor-mediated excessive heart function reduction.

Wedbush

Laura Chico

Outperform

downgrade

$40 -> $35

2025-06-27

Reason

Wedbush

Laura Chico

Price Target

$40 -> $35

2025-06-27

downgrade

Outperform

Reason

Wedbush analyst Laura Chico lowered the firm's price target on Edgewise Therapeutics to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for sevasemten in DMD such as the patient population to be studied, the firm says.

Truist

Buy

maintain

$50

2025-06-26

Reason

Truist

Price Target

$50

2025-06-26

maintain

Buy

Reason

Truist keeps a Buy rating with a $50 price target on Edgewise Therapeutics after the company's updates on phase 2 data from the ongoing DMD - Duchenne muscular dystrophy - study, regulatory update on BMD - Becker Muscular Dystrophy - that was in-line with the firm's base case, and data update from BMD OLE MESA. Truist notes that it expects the stock to be slightly weak on the regulatory feedback but also sees this as a buying opportunity, adding that given the data presented, the firm continues to see potential for sevasemten in both BMD and DMD.

Wedbush

Laura Chico

Buy

Maintains

$43

2025-04-21

Reason

Wedbush

Laura Chico

Price Target

$43

2025-04-21

Maintains

Buy

Reason

Scotiabank

Louise Chen

Buy

Hold

Downgrades

$50 → $14

2025-04-03

Reason

Scotiabank

Louise Chen

Price Target

$50 → $14

2025-04-03

Downgrades

Buy

Hold

Reason

Scotiabank analyst Louise Chen downgraded Edgewise Therapeutics to Sector Perform from Outperform with a $14 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Edgewise Therapeutics Inc (EWTX.O) is -7.20, compared to its 5-year average forward P/E of -10.82. For a more detailed relative valuation and DCF analysis to assess Edgewise Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.82

Current PE

-7.20

Overvalued PE

-3.81

Undervalued PE

-17.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.20

Current EV/EBITDA

-4.76

Overvalued EV/EBITDA

-0.57

Undervalued EV/EBITDA

-13.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00